Search

The Small and Large Magellanic Clouds are the only galaxies outside our own in which radio pulsars have been discovered to date. The sensitivity of the MeerKAT radio interferometer offers an opportunity to search for a population of more distant extragalactic pulsars. The TRAPUM (TRansients And PUlsars with MeerKAT) collaboration has performed a radio-domain search for pulsars and transients in the dwarf star-forming galaxies Sextans A and B, situated at the edge of the Local Group 1.4 Mpc away. We conducted three 2-h multibeam observations at L band (856–1712 MHz) with the full array of MeerKAT. No pulsars were found down to a radio pseudo-luminosity upper limit of 7.9 |$\pm$| 0.4 Jy kpc |$^{2}$| at 1400 MHz, which is 28 times more sensitive than the previous limit from the Murriyang telescope. This luminosity is 30 per cent greater than that of the brightest known radio pulsar and sets a cut-off on the luminosity distributions of the entire Sextans A and B galaxies for unobscured radio pulsars beamed in our direction. A fast radio burst was detected in one of the Sextans A observations at a dispersion measure (DM) of 737 pc cm |$^{-3}$|⁠. We believe this is a background event not associated with the dwarf galaxy due to its large DM and its signal-to-noise ratio being strongest in the wide-field incoherent beam of MeerKAT. [ABSTRACT FROM AUTHOR]

Galactic plane radio surveys play a key role in improving our understanding of a wide range of astrophysical phenomena. Performing such a survey using the latest interferometric telescopes produces large data rates necessitating a shift towards fully or quasi-real-time data analysis with data being stored for only the time required to process them. We present here the overview and set-up for the 3000-h Max-Planck-Institut für Radioastronomie (MPIfR)–MeerKAT Galactic Plane Survey (MMGPS). The survey is unique by operating in a commensal mode, addressing key science objectives of the survey including the discovery of new pulsars and transients and studies of Galactic magnetism, the interstellar medium and star formation rates. We explain the strategy coupled with the necessary hardware and software infrastructure needed for data reduction in the imaging, spectral, and time domains. We have so far discovered 78 new pulsars including 17 confirmed binary systems of which two are potential double neutron star systems. We have also developed an imaging pipeline sensitive to the order of a few tens of micro-Jansky (⁠|$\mu{\rm Jy}$|⁠) with a spatial resolution of a few arcseconds. Further science operations with an in-house built S-band receiver operating between 1.7 and 3.5 GHz are about to commence. Early spectral line commissioning observations conducted at S-band, targeting transitions of the key molecular gas tracer CH at 3.3 GHz already illustrate the spectroscopic capabilities of this instrument. These results lay a strong foundation for future surveys with telescopes like the Square Kilometre Array (SKA). [ABSTRACT FROM AUTHOR]

We present new radio continuum images of the edge-on starburst galaxy NGC 5775, from LOFAR (140 MHz) and the Karl G. Jansky Very Large Array CHANG-ES survey (1500 MHz). We trace the non-thermal radio halo up to 13 kpc from the disc, measuring the non-thermal spectral index and estimating the total equipartition magnetic field strength (≈13  |$\mu$| G in the disc and ≈7  |$\mu$| G above the plane). The radio halo has a similar extent at both frequencies, displays evidence for localized cosmic ray streaming coinciding with prominent H α filaments and vertical extensions of the regular magnetic field, and exhibits a boxy morphology especially at 140 MHz. In order to understand the nature of the disc–halo flow, we extend our previous model of cosmic ray propagation by implementing an iso-thermal wind with a tunable 'flux tube' (approximately hyperboloidal) geometry. This updated model is successful in matching the vertical distribution of non-thermal radio emission, and the vertical steepening of the associated spectral index, in a consistent conceptual framework with few free parameters. Our new model provides the opportunity to estimate the mass outflow driven by the star formation process, and we find an implied rate of |$\dot{M}\approx 3$| – |$6\, \mathrm{M_{\odot }\, yr^{-1}}$| (≈40–80 per cent of the star formation rate) if the escape velocity is reached, with substantial uncertainty arising from the poorly understood distribution of interstellar medium material entrained in the vertical flow. The wind may play a role in influencing the vertical gradient in rotational velocity. [ABSTRACT FROM AUTHOR]

Immune checkpoint inhibitors have revolutionized care for many cancer indications, with considerable effort now being focused on increasing the rate, depth, and duration of patient response. One strategy is to combine immune strategies (for example, ctla-4 and PD-1/L1-directed agents) to harness additive or synergistic efficacy while minimizing toxicity. Despite encouraging results with such combinations in multiple tumour types, numerous clinical challenges remain, including a lack of biomarkers that reliably predict outcome, the emergence of therapeutic resistance, and optimal management of immune-related toxicities. Furthermore, the selection of ideal combinations from the myriad of immune, systemic, and locoregional therapies has yet to be determined. A longitudinal network-based approach could offer advantages in addressing those critical questions, including long-term follow-up of patients beyond individual trials. The molecular cancer registry Personalize My Treatment, managed by the Networks of Centres of Excellence nonprofit organization Exactis Innovation, is uniquely positioned to accelerate Canadian immuno-oncology (io) research efforts throughout its national network of cancer sites. To gain deeper insight into how a pan-Canadian network could advance research in io combinations, Exactis invited preeminent clinical and scientific advisors from across Canada to a roundtable event in November 2017. The present white paper captures the expert advice provided: leverage longitudinal patient data collection; facilitate network collaboration and assay harmonization; synergize with existing initiatives, networks, and biobanks; and develop an io combination trial based on Canadian discoveries. [ABSTRACT FROM AUTHOR]

Context. The new generation of broad-band radio continuum surveys will provide large data sets with polarization information. New algorithms need to be developed to extract reliable catalogs of linearly polarized sources that can be used to characterize those sources and produce a dense rotation measure (RM) grid to probe magneto-ionized structures along the line of sight via Faraday rotation. Aims. The aim of the paper is to develop a computationally efficient and rigorously defined source-finding algorithm for linearly polarized sources. Methods. We used a calibrated data set from the LOw Frequency ARray (LOFAR) at 150 MHz centered on the nearby galaxy M 51 to search for polarized background sources. With a new imaging software, we re-imaged the field at a resolution of 18″ × 15″ and cataloged a total of about 3000 continuum sources within 2.5° of the center of M 51. We made small Stokes Q and U images centered on each source brighter than 100 mJy in total intensity (201 sources) and used RM synthesis to create corresponding Faraday cubes that were analyzed individually. For each source, the noise distribution function was determined from a subset of the measurements at high Faraday depths where no polarization is expected; the peaks in polarized intensity in the Faraday spectrum were identified and the p-value of each source was calculated. Finally, the false discovery rate method was applied to the list of p-values to produce a list of polarized sources and quantify the reliability of the detections. We also analyzed sources fainter than 100 mJy but that were reported as polarized in the literature at at least another radio frequency. Results. Of the 201 sources that were searched for polarization, six polarized sources were detected confidently (with a false discovery rate of 5%). This corresponds to a number density of one polarized source per 3.3 square degrees, or 0.3 source per square degree. Increasing the false discovery rate to 50% yields 19 sources. A majority of the sources have a morphology that is indicative of them being double-lobed radio galaxies, and the ones with literature redshift measurements have 0.5 < z < 1.0. Conclusions. We find that this method is effective in identifying polarized sources, and is well suited for LOFAR observations. In the future, we intend to develop it further and apply it to larger data sets such as the LOFAR Two-meter Survey of the whole northern sky, LOTSS, and the ongoing deep LOFAR observations of the GOODS-North field. [ABSTRACT FROM AUTHOR]

With Low-Frequency Array (LOFAR) observations, we have discovered a diverse assembly of steep spectrum emission that is apparently associated with the intracluster medium (ICM) of the merging galaxy cluster Abell 2034. Such a rich variety of complex emission associated with the ICM has been observed in few other clusters. This not only indicates that Abell 2034 is a more interesting and complex system than previously thought but it also demonstrates the importance of sensitive and high-resolution, low-frequency observations. These observations can reveal emission from relativistic particles which have been accelerated to sufficient energy to produce observable emission or have had their high energy maintained by mechanisms in the ICM. The most prominent feature in our maps is a bright bulb of emission connected to two steep spectrum filamentary structures, the longest of which extends perpendicular to the merger axis for 0.5 Mpc across the south of the cluster. The origin of these objects is unclear, with no shock detected in the X-ray images and no obvious connection with cluster galaxies or AGNs. We also find that the X-ray bright region of the cluster coincides with a giant radio halo with an irregular morphology and a very steep spectrum. In addition, the cluster hosts up to three possible radio relics, which are misaligned with the cluster X-ray emission. Finally, we have identified multiple regions of emission with a very steep spectral index that seem to be associated with either tailed radio galaxies or a shock. [ABSTRACT FROM AUTHOR]

BACKGROUND In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had metastatic, castration-resistant prostate cancer associated with a deleterious BRCA alteration. Data are needed to confirm and expand on the findings of the phase 2 study. METHODS In this randomized, controlled, phase 3 trial, we enrolled patients who had metastatic, castration-resistant prostate cancer with a BRCA1, BRCA2, or ATM alteration and who had disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). We randomly assigned the patients in a 2:1 ratio to receive oral rucaparib (600 mg twice daily) or a physician’s choice control (docetaxel or a second-generation ARPI [abiraterone acetate or enzalutamide]). The primary outcome was the median duration of imaging-based progression-free survival according to independent review. RESULTS Of the 4855 patients who had undergone prescreening or screening, 270 were assigned to receive rucaparib and 135 to receive a control medication (intention-to-treat population); in the two groups, 201 patients and 101 patients, respectively, had a BRCA alteration. At 62 months, the duration of imaging-based progression-free survival was significantly longer in the rucaparib group than in the control group, both in the BRCA subgroup (median, 11.2 months and 6.4 months, respectively; hazard ratio, 0.50; 95% confidence interval [CI], 0.36 to 0.69) and in the intention-to-treat group (median, 10.2 months and 6.4 months, respectively; hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001 for both comparisons). In an exploratory analysis in the ATM subgroup, the median duration of imaging-based progression-free survival was 8.1 months in the rucaparib group and 6.8 months in the control group (hazard ratio, 0.95; 95% CI, 0.59 to 1.52). The most frequent adverse events with rucaparib were fatigue and nausea. CONCLUSIONS The duration of imaging-based progression-free survival was significantly longer with rucaparib than with a control medication among patients who had metastatic, castration-resistant prostate cancer with a BRCA alteration. [ABSTRACT FROM AUTHOR]

BACKGROUND Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progressionfree survival and safety. RESULTS Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [Cl], 0.56 to 0.86; P = 0.001). Avelumab also significantly prolonged overall survival in the PD-Ll-positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% Cl, 0.40 to 0.79; P<0.001). The median progression-free survival was 3.7 months in the avelumab group and 2.0 months in the control group in the overall population (hazard ratio for disease progression or death, 0.62; 95% Cl, 0.52 to 0.75) and 5.7 months and 2.1 months, respectively, in the PD-Ll-positive population (hazard ratio, 0.56; 95% Cl, 0.43 to 0.73). The incidence of adverse events from any cause was 98.0% in the avelumab group and 77.7% in the control group; the incidence of adverse events of grade 3 or higher was 47.4% and 25.2%, respectively. CONCLUSIONS Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432). [ABSTRACT FROM AUTHOR]